4.6 Review

Promoting Remyelination in Multiple Sclerosis-Recent Advances

Journal

DRUGS
Volume 73, Issue 18, Pages 2017-2029

Publisher

ADIS INT LTD
DOI: 10.1007/s40265-013-0146-8

Keywords

-

Funding

  1. Chief Scientist's Office, Scotland
  2. Centre for Clinical Brain Sciences, University of Edinburgh

Ask authors/readers for more resources

We review the current state of knowledge of remyelination in multiple sclerosis (MS), concentrating on advances in the understanding of the pathology and the regenerative response, and we summarise progress on the development of new therapies to enhance remyelination aimed at reducing progressive accumulation of disability in MS. We discuss key target pathways identified in experimental models, as although most identified targets have not yet progressed to the stage of being tested in human clinical trials, they may provide treatment strategies for demyelinating diseases in the future. Finally, we discuss some of the problems associated with testing this class of drugs, where they might fit into the therapeutic arsenal and the gaps in our knowledge.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available